Mazdutide vs Dulaglutide
Head-to-head comparison of Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) and Dulaglutide (Recombinant GLP-1 receptor agonist Fc fusion protein) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Mazdutide | Dulaglutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist | Recombinant GLP-1 receptor agonist Fc fusion protein |
| Molecular Weight | ~5,000 Da | ~63,000 Da |
| Half-Life | 5-7 days | About 5 days |
| Amino Acids | 37 | N/A |
| Typical Dose | 1-6 mg weekly in obesity trials | 0.75-4.5 mg weekly |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 28 | 700 |
| Research Status | Clinical | Approved |
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
Dulaglutide Benefits
- ✓modest weight loss
- ✓lower A1c
- ✓weekly dosing convenience
- ✓cardiometabolic benefit
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
Dulaglutide Dosing
0.75-4.5 mg SC weekly|Increase based on response and tolerance|Administer on the same day each week
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Dulaglutide Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠injection-site reactions
Research Overview
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Dulaglutide
Dulaglutide has repeatedly shown small-to-moderate reductions in body weight alongside glycemic improvement in large diabetes trials. It is a useful comparator for GLP-1 receptor agonist effects on appetite and weight.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.